David Bell

Grifols Innovation & New Technologies Ltd. provides research and experimental development services in biotechnology sector. The company was founded on December 21, 2015 and is headquartered in Dublin, Ireland.

Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The company is based in Los Angeles, CA.

GigaGen, Inc. engages in the provision of single cell droplet technology to clinical researchers and physicians. The firm's patent-pending technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize genetic data from cells circulating in blood. Its technology can be applied in immunology, infectious disease monitoring, noninvasive prenatal diagnostics, and noninvasive cancer detection. The company was founded by David S. Johnson and Everett Meyer in 2010 and is headquartered in South San Francisco, CA.

Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA.

Alkahest, Inc. operates as biopharmaceutical company. It focuses on developing of treatments for neurodegenerative and age-related diseases. The company is headquartered in San Carlos, CA.

Knapp, Petersen & Clarke PC is a law firm that offers a variety of legal services. The private company is based in Glendale, CA. The firm emphasizes its creativity and accessibility in providing these services.

BPC Plasma, Inc. manufactures pharmaceutical products. It offers the hyper immunoglobulin Nabi-HB, a key product used in the prevention of hepatitis B. The company was established in 2007 and is headquartered in Boca Raton, FL.

Part of Theriva Biologics, Inc., VCN Biosciences SL is a clinical-stage immuno-oncology company based in Barcelona, Spain. The Spanish company focuses on developing the next generation of oncolytic adenoviruses that can obtain clinical activity after systemic administration and remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences' lead product, VCN-01, is a unique oncolytic adenovirus being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. The company was founded by Ramon Alemany. VCN Biosciences was acquired by Theriva Biologics, Inc. from Grifols SA on March 10, 2022 for $92.02 million.

Interstate Blood Bank, Inc. engages in the provision of human blood and blood components to the therapeutic and diagnostic industries. The company was founded in 1949 and is headquartered in Memphis, TN.